Adefovir Dipivoxil (Hepsera)
Customize your policy alerts
Sign up for Oscar Health Policy PG081 alerts
Get alerted when Policy PG081 changes without checking for updates manually.
Monitor payer policy activity
This guideline governs prior authorization, initial coverage, and reauthorization of oral adefovir dipivoxil (Hepsera) for members with chronic hepatitis B virus infection. It requires specialist involvement, age and diagnosis criteria, supporting documentation, and evidence of therapeutic response for continued therapy.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy
Covered when ALL of the following criteria are met. If these prior authorization criteria are met, Adefovir Dipivoxil (Hepsera) will be approved for up to 6 months.
ALL of the following
- The requested medication is being prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist.
- The member is 12 years of age or older.
- The member has a documented diagnosis of chronic hepatitis B virus (HBV) infection confirmed by appropriate laboratory test(s).
- The member is unable to use or has tried and failed entecavir (Baraclude) or tenofovir (Vemlidy).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.